Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease

Movement Disorders

Volumn 13, Issue 6, 1998, Pages 871-876

  Brotchie, Jonathan M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Dyskinesia; MPTP; Parkinson's disease

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DOPAMINE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE ANTAGONIST; SEROTONIN AGONIST;

BASAL GANGLION; DRUG EFFICACY; DYSKINESIA; HUMAN; LONG TERM CARE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY; SYMPTOM;

EID: 0031739073     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130603     Document Type: Review

References (14)

1. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
2. Blanchet PJ, Gomez-Mancilla B, Bedard PJ. Dopa-induced 'peak-dose' dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J Neural Transm Suppl 1995;45:103-112.
3. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
4. Maneuf YP, Mitchell U, Crossman AR, Brotchie JM. On the role of enkephalin co-transmission in the GABAergic striatal efferents to the globus pallidus. Exp Neurol 1994;125:65-71.
5. Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging 1996;9:149-158.
6. Trabucchi M, Bassi S, Frattola L. Effect of naloxone on the 'on-off' syndrome in patients receiving long-term levodopa therapy. Arch Neurol 1982;39:120-121.
7. Sandyk R, Snider SN. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease. Am J Psychiatry 1986;143:118.
8. Gomez-Mancilla B, Bedard PJ. Effect of non-dopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys, Clin Neuropharmacol 1993; 16:418-427.
9. Rascol O, Fabre N, Blin O, et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov Disord 1994;9:437-440.
10. 2 antagonist, idazoxan, in patients with Parkinson's disease. Mov Disord 1997;12:111.
11. 2-adrenergic receptor antagonists reduce symptoms in animal models of L-dopa-induced dyskinesia. Proceedings of the Society for Neuroscience (USA) 1997;23:291.4.
12. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-1858.
13. Brotchie JM, Fox S, Henry B, et al. The cannabinoid receptor antagonist SR141716A reduces L-dopa-induced dyskinesia in the MPTP-treated primate model of Parkinson's disease. Br J Pharmacol 1997;123:67P.
14. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996;46:1548-1551.